Pharmacogenomic Testing in Pain Management and Behavioral Health: A Pharmacist Perspective

• By: Ronnie Moore, PharmD Ludovick Youmbi, PharmD Angelo O’Neill, MSW Allure Specialty Pharmacy
• January 1st, 2020
• behavioral health, CYP2D6 enzyme, opioid use, pain management, personalized medicine, PGx testing, pharmacogenomics, treatment resistant depression
• 1711    0

Pain, in its many forms (e.g., nociceptive, neuropathic, inflammatory, etc.), affects upwards of 100 million people in the United States resulting in costs reaching $600 billion per year.1 Treatment of pain symptoms through the inappropriate prescribing and use of opioids has fueled an opioid abuse...

Relief from Decades of Treatment-Resistant Depression Comes with Metabolite Replacement Therapy Trial

• By: Fatima Bhojani Brain & Behavior Research Foundation (BBRF)
• July 1st, 2018
• cerebral folate deficiency, folate deficiency, major depression, metabolic disorders, neurotransmitters, serotonin, suicidal ideation, treatment resistant depression
• 2799    0

Bruce had tried everything. And yet, for three decades, he could not find any relief from his debilitating depression and suicidal thoughts. Twenty medications. Electroconvulsive therapy. Countless hours of counseling and cognitive behavioral therapy. Nothing had worked. Of the 15 million...

The Brain & Behavior Research Foundation: A Personal Perspective

• By: Ira H. Minot, LMSW Behavioral Health News
• July 1st, 2018
• brain disorders, depression treatment, Mental illness research, neuroscience, recovery, schizophrenia research, stigma, treatment resistant depression
• 1730    0

The Brain & Behavior Research Foundation (BBRF) is unraveling the many mysteries of mental illness, autism spectrum disorders, and many other diseases and disorders of the brain. I would like to thank Dr. Jeffery Borenstein and his team at BBRF for their help in bringing our salute to their...